Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

Investors in CRISPR Therapeutics AG (NASDAQ:CRSP) have tasted that bitter downside in the last year, as the share price dropped 46%. That contrasts poorly with the market return of 15%. At least the ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Stock price predictions for 2025 are increasingly "meta." No, not the Facebook parent, but rather the idea that investments are increasingly self-referential rather than reliant on outside ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

The S&P 500 and growth-focused ETFs, like IVW, are experiencing sharp declines. Read why I maintain my buy rating on Vanguard ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Explore highly-rated Vanguard index funds for long-term investing and build a well-diversified portfolio. Check our list of ...

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their ...

Vanguard's current lineup of 266 mutual funds is as diverse as it gets, ranging from low-cost index funds to actively managed, hedge-fund-style strategies such as market-neutral. But for retail ...

Large-cap stocks are one of the most popular ways to invest in the market. These companies have the deepest pockets, and ...